Table 3

Differences in beta coefficients (log ORs) of predictors included in the development model, when calculated in the derivation data set and then in the validation data set

Item	Derivation cohort		Validation cohort
Item	Beta estimate	SE of estimate	Beta estimate	SE of estimate	Episodes, n
Acute myeloid leukaemia	0.65	0.26	0.31	0.36	52
Ewing’s sarcoma	−0.64	0.66	−1.08	0.42	71
Germ cell tumour	−0.07	0.88	−13.14	72.64	5
Hepatoblastoma	0.48	0.57	1.04	0.66	12
High-grade brain tumour	−0.34	0.46	0.32	0.3	80
Hodgkin’s lymphoma	−0.41	0.7	−1.07	1.07	13
High-risk neuroblastoma	0.92	0.66	−0.35	0.34	78
Langerhans cell histiocytosis	−14.1	1025.44	1.01	1.27	3
Low-grade brain tumour	−14.16	677.94	0.24	0.47	26
Neuroblastoma	0.47	0.49	−16.44	83.28	2
Non-Hodgkin’s lymphoma	−0.47	0.32	−0.14	0.33	69
Osteosarcoma	−1.19	0.57	0.18	0.33	57
Other tumour	0.8	0.77	−0.93	0.78	17
Retinoblastoma	0.55	0.86	1.05	0.93	5
Rhabdomyosarcoma	−0.24	0.32	−0.18	0.35	67
Sarcoma	0.19	0.82	18.92	115.14	2
Wilms tumour	−0.49	0.66	0.59	0.41	37
Temperature (per °C from 37)	0.57	0.14	0.18	0.14	1152
Clinical impression of ‘Severely unwell’	0.79	0.19	1.29	0.27	1152
Haemoglobin (per g/dL)	0.18	0.05	0	0.06	1152
Natural log (total white cell count)	−0.3	0.1	−0.16	0.09	1152
Natural log (absolute monocyte count)	−0.21	0.06	0.01	0.06	1152